Healthcare Plans Using Analytics to Improve Health Literacy Patient Engagement and Outcomes with Bob Farrell mPulse

Rick Davis, patient advocate and Founder of AnCan, is building and operating virtual peer-to-peer support groups to allow patients to connect with others who have direct experience with their condition.  These groups can provide accurate information, foster connections among participants, and serve as a check on medical misinformation. With the growing acceptance of virtual meetings, this approach overcomes geographic, physical, and psychosocial barriers that might otherwise prevent participants from attending on-site meetings. Rick explains, "The mission is to make each person and each patient a better advocate for themselves. That's really what we try to do, and we do that through empowering patients with peer knowledge. We introduce patients to other peers who have been through what these people are facing right now, not only patients, but also their care partners, and through their experience, we hope that these patients and care partners will become more expert in managing their own situation."   "In 2007, when I was first diagnosed with stage three cancer, I attended a physical meeting, and I realized that so many people cannot attend physical meetings because one, they may have a geographical disability, they may have a physical disability, or they may have a psychosocial disability. If we only allow people to exchange views when they're physically in front of each other, it's very limiting. And so I started to look and see what existed in terms of virtual communication. And back in the day, there was very, very little. And that was the motivation that got me started."  "People come into a group, and they hear things that they just wouldn't hear otherwise. And that's why it's so valuable. It's so incredibly valuable. I mean, we had a group last night where a guy came in facing a situation, and by total coincidence, there was somebody from his own city in there who knew the docs that he'd been dealing with, understood the frustration he'd been going through, had been through it himself, and shared his experience. Well, you can't buy that."   #AnCan #AnCanSupport #VirtualSupport #CancerSupport #PeerSupport #PatientAdvocay #DigitalHealth ancan.org Download the transcript here  

Bob Farrell, CEO of mPulse, is using digital technology, data analytics and AI to improve the relationship between health plans and their members in order to improve health outcomes and operational efficiency. Bob introduces the concept of HXI, Health Experience and Insights, as a framework that unites data, intelligence, and personalized communication to provide tools to enage members at the best time and by the preferred methods with appropriate information at the right time. Analyzing claims data enables plans to identify high-risk patients, promote preventive care, and build health literacy. Bob explains, "The mission of mPulse, and this has really been the mission of the company since its founding in 2015, is to improve the health outcomes of our customers' members and patients. So we're looking to close gaps in care. We're looking to increase literacy so that members and patients can understand their health plans. So providers can take charge of healthcare and improve those outcomes. And while we're doing that, we try to help our customers improve their operational efficiencies. Most of our customers are health plans and they range from small community plans to large nationals. The 60 largest plans are our customers. We have a wide array of customers and continue to expand on that base, both with new customers and by doing more with the customers that we have."   "Health plans are not known to be the early adopters of technology. So you're right. A lot of them are still transitioning from older ways of doing things. But in general, health plans have a huge trust issue with their members, and it has really resulted from a lack of engagement, a lack of positive experience. So we see a lot of health plans looking to embrace technology to improve the member experience, make sure that those members are getting outreach. Not just now and then, but during the whole course of their consumer health journey, so that they can be aware of what things they have available to them, so that they can easily adjudicate claims and easily find providers."    #mPulse #HXI #PersonalizedCare #HealthExperienceInsights #DigitalHealth mPulse.com Download the transcript here  

Rick Pierce, Co-Founder and CEO of Decoy Therapeutics. is using AI and machine learning to accelerate drug discovery and is developing broad-acting antivirals using peptide conjugates that target a shared invasion mechanism of hundreds of viruses.  The company is using small language models and a high-speed peptide synthesizer to dramatically reduce drug creation time. Rick predicts that the future of drug discovery will combine AI-driven design with advanced biological models, such as organoids, to better predict drug toxicity and efficacy. Rick explains, "Decoy Therapeutics was founded years ago, during the COVID era. And what we've learned during that was that in order to develop drugs rapidly and scale up their manufacturing, we needed to use machine learning and AI. And the drugs that we're looking at developing today as a result of that are broad-acting antivirals that can be used against multiple viruses. So one drug can be used against multiple viruses like Flu, COVID, and RSV." "So we chose antivirals as a space because viruses have what is called polypharmacology, and in plain layman's terms, what that means is that about 250 of these viruses share the same invasion machinery, meaning the way the virus enters the healthy cells is shared across all those viruses. It's slightly different in each of those viruses, but effectively for drug development, very similar."   "That allows us to use peptides, which are also alpha helices, to be able to design drugs with AI and machine learning that physically block the invasion machinery and thus basically the virus from binding to a healthy cell. Peptides are uniquely positioned as drugs for this set of viral targets. Again, it's a rich set of targets among 250 viruses across multiple viral families."   #DecoyTherapeutics #PeptideConjugates #BroadSpectrumAntiviral #AIinBiotech #NextGenMedicine   decoytx.com Download the transcript here  

Dr. Kumar Dharmarajan, cardiologist and geriatrician and Co-Founder and Chief Medical Officer at World Class Health, is  bringing concierge healthcare to employees of self-insured companies.   The platform includes a global network of top-tier doctors and nurse navigators. Directly negotiating with providers reduces costs and reduces administrative and financial friction for patients seeking planned procedures. The model also reduces friction for physicians by providing them with complete patient records and ensuring prompt payment. Kumar explains, "We are a global, medically led center of excellence platform. So, by that, we have top doctors and top hospitals around the world, including the United States and many other countries, and we help patients access that network. We have pre-negotiated rates via our nurse navigators. We really believe in the power of nurses to help patients make healthcare decisions that may be valuable and important to them. And those nurses will work with the patient before, during, and after their care episode, whether that physician they access is local, in their own communities, or somewhere else around the world. And right now, we are partnering with large self-insured companies around the world and offering our product, in addition to the network they have through their usual insurer." "We are looking for employees of self-insured large companies. Our specific target has been largely knowledge workers, so these are employees in technology, financial services, and other knowledge industries. And the reason we feel that is one, our global network may be really appealing to them because many knowledge workers come from different parts of the world, Asia, Europe, Latin America, etc. And second, our nurses and our strong concierge model, which we built with experts from Stanford and Johns Hopkins International, have created a truly white-glove experience. So not only are they high-quality, highly qualified providers, top 1% doctors, hospitals around the world, but it's also a white glove service to help patients deal with all the administrative minutiae and challenges we all experience in healthcare. And we believe that's well powered and tailored to the knowledge industry." #WorldClassHealth #SelfInsured #ConciergeCare #NurseNavigators #DigitalHealth worldclasshealth.com Download the transcript here

Brent Dial, Founder and CEO of Beek Health, has built a platform that addresses patient information fragmentation by aggregating data from patient portals and providing direct access to lab testing. Health literacy is key to preventing chronic diseases, and AI is being used to scale the delivery of personalized health information. Identifying relevant biomarkers and early warning signs supports proactive health management that can alter long-term health outcomes. Brent explains, "Beek Health is re-imagining healthcare by finally putting the individual at the center of their health journey. While we talk about patient-centric or customer-centric or shared decision-making, it's not real in practice, and it's for good and for very clear reasons. There's information asymmetry, there's information overload, and then information is quite fragmented." "Currently, we have three subscription tiers. The first option is the basic plan, which gives you platform access to synthesize and connect with multiple patient portals, as many as you have. The average individual has at least two patient portals, and it's estimated you'll see 17 different providers in your lifetime. So that's a lot of data spread out across different systems. So, one, you can sync. We have over 40,000 endpoints or provider locations where you can sync your patient portal information in one unified dashboard. All the dashboards look different."  "Second, you'll have access to labs anytime you need them. And so labs are woefully underutilized for health tracking: 70% of diagnoses are based on lab results, so you can access them anytime you need to. We partner with LabCorp, which has over 2,000 locations, and you'll receive your results within 48 hours. In addition, we're adding cost navigation, cost estimate tools, and some more fun features on our roadmap, but that just gives you basic access for a year for $99."   #BeekHealth #HealthInYourHands #OwnYourHealthData #HealthTech #DigitalHealth #PatientEmpowerment #HealthcareReimagined #ConnectedHealth #FutureOfHealth beekhealth.com Download the transcript here

Dr. Asher Eghbali, Co-Founder of Fuerte, has developed a platform to address the significant communication challenges between healthcare providers and pharmaceutical industry representatives. The goal is to streamline this relationship by replacing inefficient scheduling methods, and eliminate miscommunication and missed meetings to reduce frustrations and wasted time. The app is designed to combine professional networking with social media elements, including user profiles and notifications, to help build stronger, long-lasting professional relationships that benefit everyone involved. Asher explains, "Within the life science companies and pharmaceutical reps, as we know, they're working very hard to commercialize medications and new drugs, new therapies that come out there that they want to get into patients' hands. But sometimes they have a very hard time scheduling and putting in time to go to the doctor's office. Traditionally, they conduct a lunch-and-learn session or a coffee consult, where they come on-site to a doctor's office or a hospital setting."   "Right now, to schedule that appointment, it's being done where the medical assistant or the office manager is writing down that individual's name on some kind of paper calendar, at most, maybe some kind of Google sheet, or a Google Meet account that they have within the office section. And that's the way that they're scheduling it. Healthcare reps are sometimes cold walking in, sometimes they're cold calling. They're putting in a lot of effort. They're working very hard to figure out how to get in and educate providers and their staff on new advancements." "What Fuerte hopes to do with a streamlined communication platform is make it very easy for the providers to find the reps and the reps to find providers to keep in touch with each other, to search each other by disease state, by therapeutic drug, by medical advancement, and to have a shared calendar system that they can keep in constant communication and contact." fuerteapp.com Download the transcript here

Scott Pescatore, Executive VP of the Rare Diseases Business at Recordati, is focused on rare and ultra-orphan diseases with high unmet needs by acquiring promising compounds from other companies and advancing them through development and approval. An example is the company's drug Isturisa, acquired from Novartis, which is an FDA-approved effective treatment for patients with Cushing syndrome, a rare endocrine condition. Raising awareness of rare diseases among physicians, patients, and the general public is a priority for Recordati to improve diagnosis rates and clinical trial participation, and to encourage more research and funding in the rare disease space. Scott explains, "We have two primary divisions at Recordati. One is our specialty primary care business, and the other is the rare disease business, which I have the honor and privilege to look after. And we have a very simple sort of work ethic or business mantra, if you will, and that's focused on the few. And we really dedicate ourselves to focusing on disease areas and patient groups and therapeutic areas that have a high unmet need and really low or limited options for patients. And really focusing on diseases and areas that are rare and considered ultra-orphan by the definitions in the US, where really there's a very small patient base. And that's where we began back in 2007, when the rare disease business was formed. And that's really what our focus has been since then. And we continue to focus on this segment of the market." "So Isturisa is really a fantastic product. We acquired this product through a deal we did with Novartis Pharmaceuticals back in 2019, and this product has FDA approval for patients who have endogenous hypercortisolemia with Cushing syndrome. So it's quite a nasty disease, but it's a very efficacious product. The product is what's considered a cortisol inhibitor in the blocks in a particular enzyme to help normalize hypercortisolemia in patients with Cushing syndrome. And Cushing syndrome, for those who aren't familiar, is a rare endocrine condition that really has a significant impact on patients' quality of life, on the caregivers, on the families. And the indication I mentioned was supported by quite robust phase 3 trials."  #Recordati #RareDisease #FocusedontheFew #CushingSyndrome #IMCD #CastlemansDisease recordati.com Download the transcript here  

Martin Burns, CEO of Bruin Biometrics, is focused on preventing pressure injuries, which are often not detected through visual and tactile assessments because damage starts invisibly under the skin. The Bruin scanner technology identifies pressure injuries by measuring sub-epidermal moisture, which can predict later tissue death, highlighting the condition that can be treated before it develops further. This handheld device is skin tone agnostic, addressing a significant health disparity and providing an objective number indicating the presence of excess fluid, allowing clinicians to act quickly. Martin explains, "They are surprisingly common, and I emphasize surprisingly because pressure injuries are typically not talked about in the mainstream, but actually they affect about three to three and a half million patients a year in the US. And really shockingly, of those three to three and a half million, about 60,000 people die from them every year. So think about that as in the list of the top 10 leading causes of mortality in the United States, which is the surprising part. When you speak to friends and relatives, they've often heard of them potentially as bedsores, but nobody really has an appreciation of just how significant they are. How widespread or how deadly."   "The initial stages of it are imperceptible to any practitioner, but are actually measurable by objective technologies, and they don't become visibly manifest or physically manifest until much later. And what happens is they end up breaking the skin surface. As you can imagine, every time the skin is broken is an opening for infections and significant complications, which actually is the thing that ends up causing huge amounts of additional lengths of stay and costly treatments. And to the extent that those don't work, mortality." "Thankfully, our scanner is one in which the mechanism it uses disregards skin tone entirely. In other words, skin color doesn't matter for the scanner. What we are measuring is an increase or a decrease in fluid at the specific site that we're measuring. And so it's skin tone agnostic, which is rather brilliant because dark skin tone patients die at a rate four times more than any other cohort, which is an absolute travesty and one in which it simply doesn't need to happen. And our scanner is a leading reason why it doesn't need to happen." #BruinBiometrics #Prevention #PressureInjuries #HospitalSafety #PressureInjuryPrevention #PatientSafety #Hospitals bruinbiometrics.com Download the transcript here

Robert Jacks, President and CEO of Sparrow Pharmaceuticals, identifies that an elevated cortisol level is a newly recognized cause of treatment-resistant type 2 diabetes. A significant portion of patients with diabetes who do not respond to standard treatments, including GLP-1 agonists, have underlying high cortisol. Sparrow has developed a drug designed to lower cortisol levels inside cells, directly addressing the underlying driver of the disease, and to be used as a complement to existing treatments. This concept of targeting cortisol-driven resistance could be extended to other conditions, such as treatment-resistant hypertension. Robert explains, "I feel as though Sparrow has come full circle, actually, with the mechanism of our drug. Originally, we have a drug that targets HSD-1. We can talk about what that is, but it's involved in intracellular cortisol regulation. This was a class of drugs that was originally developed targeting cardiometabolic diseases like type 2 diabetes. And the drugs had some moderate efficacy, but they weren't well differentiated in a broad population and largely were just discontinued for commercial reasons." "Our company was founded a number of years ago based on the idea that these drugs had real potential but hadn't been used in the right patient population. And that being the patient population with the disease that we know is driven by excess cortisol toxicity, because that's aligned with the mechanism, as I was mentioning. So we generated some really interesting data in a rare disease called Endogenous Cushing syndrome. This is a very severe orphan disease with patients who have very severely elevated cortisol, showing in fact that yes, this mechanism does seem like it could have a very major impact in the right patient population." "Simultaneously, another company published some data showing that actually there's a very large population of people with treatment-resistant type 2 diabetes, a very high level of medical need, and that their underlying disease actually is being driven by elevated levels of cortisol. And so when you bring together the data that we generated and what appears to be a large amount needed in a large population, it seems like we may have the perfect solution for that. So we've refocused our efforts on a broad population of treatment-resistant type 2 diabetes in patients whose disease is being impacted or driven by elevated cortisol levels."  #SparrowPharmaceuticals #Type2Diabetes #CardiometabolicDisease #CortisolRegulation #Cortisol #GLP1 #RareDisease sparrowpharma.com Download the transcript here

Jesse Levey, CEO and Founder of Longevity Health, has a focus on extending the health span not just the lifespan of more people by providing access to tools and preventative health information. Lessons learned from expensive concierge medical services are being applied to a broader population, driving down health costs and democratizing longevity medicine. Using AI to build a scalable and personalized approach to wellness not just sick care, Longevity Health aims to make an AI doctor available around the globe.  Jesse explains, "Our mission is to help a billion people live to a hundred in good health. That's the vision. And the way that we get there is by building an AI doctor trains of ed on longevity medicine and distributed around the world. We have a three-phased business model. Phase one is to take the sort of hundred-thousand-dollar-a-year longevity concierge experience and deliver it for $10,000. So we've taken this really high-end experience that combines an executive physical with a longevity concierge physician and a team to help you implement the recommendations. And we've delivered that for $10,000. That's been around for about two years."  "Phase two takes that down to $1,000 with the help of AI. So it reduces the time spent by humans and the need to spend a lot of time with clinicians. And so it's a mix between clinician time and AI interactions. And then eventually, as the regulation allows and as the technology improves, we believe that we'll be able to deliver this experience for as low as $10 a month or $100 a year via an AI doctor. And so that's the future. That's what we're building towards." #LongevityHealth #Longevity #HealthyAging #HealthSpan #FunctionalMedicine #HealthAI #Aging longevityhealth.me Download the transcript here